EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk, whose profits from blockbuster weight-loss ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

A roundup of top health news highlights Novo Nordisk's $16.5 billion deal scrutiny, Amgen's weight-loss drug controversy, ...

Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's ...

As the controlling shareholder of Novo Nordisk, a leading Danish pharmaceutical company, the takeover emerges amidst rising ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Examples include exenatide and lixisenatide. Ozempic: Novo Nordisk’s name-brand version of injectable semaglutide to help ...

European Union seeks input from rival pharmaceutical firms on Novo Holdings' $16.5 billion acquisition of Catalent.

Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...